Positive Idelalisib Data Halts Late-Stage CLL Trial – OncLive
OncLivePositive Idelalisib Data Halts Late-Stage CLL TrialOncLiveA phase III study of the PI3K-delta inhibitor idelalisib in combination with rituximab (Rituxan) has been stopped early following a positive interim analysis, according to a statement fro…
